Structured PICO summaries for doctors and healthcare professionals, covering population, intervention, comparison, outcomes, expert commentary, and references across diabetes, endocrinology, obesity, and cardiometabolic medicine.
The ROBUST study protocol describes a planned randomized trial of a social network-enhanced lifestyle intervention for obesity in Black and Hispanic adults, with no outcome results yet. PICO summary and expert commentary.
A 96-patient randomised controlled trial of manufacturer-developed autologous platelet gel versus standard dressings for chronic neuropathic diabetic foot ulcers, with PICO summary and expert commentary.
A design, recruitment, and baseline-characteristics report for the PREDIABETEXT cluster randomised trial of a digital diabetes-prevention intervention, with no efficacy outcomes yet reported. PICO summary and expert commentary.
A secondary cost-consequence and budget impact analysis of the TELE-DD trial found a nurse-led telephone program for nonadherent Type 2 diabetics with comorbid depression became cheaper per glycaemically controlled patient by 12-18 months. PICO summary and expert commentary.
A 2-centre factorial RCT in 273 Chinese adults with type 2 diabetes found the Dnurse app did not significantly improve HbA1c attainment, though systolic blood pressure fell in the app arms. PICO summary and expert commentary.
A 6-month structured anti-inflammatory diet-and-exercise programme in 542 adults with prediabetes delayed diabetes onset but did not lower 8-year incidence. PICO summary and expert commentary.
A manufacturer-funded cost-effectiveness model found the MiniMed 780G closed-loop system cost-effective versus injections with isCGM in US type 1 diabetes at $100,000 per QALY (ICER $68,402 over 4 years, $38,842 lifetime). PICO summary and expert commentary.
A small single-centre randomised trial mapped subcutaneous adipose gene-expression changes after six months of lifestyle-induced weight loss in men with metabolic syndrome. PICO summary and expert commentary.
A phase 3 open-label trial in 440 Chinese adults found the dulaglutide biosimilar LY05008 met its equivalence margin for HbA1c reduction against reference dulaglutide. PICO summary and expert commentary.
A small mechanistic RCT (n=34) found ertugliflozin did not increase proximal tubular natriuresis (the primary outcome) but did reduce fluid volume and blood pressure by week 12. PICO summary and expert commentary.
Welcome to Hormone Insight. Our mission is to support clinical decision-making with accessible, evidence-based insights from recent studies and trials.
© 2024-2026 Hormone Insight. All rights reserved.
